Attending the Society for Melanoma Research (SMR) Congress in the Big Easy allowed me to see how science continues to advance the treatment of #melanoma.
The session “What does neoadjuvant efficacy tell us about immunotherapy versus targeted efficacy across disease stages?” Presented by Dr Keith Flaherty, M.D, Mass General Research Institute reviewed the data from the Braf/Mek inhibitor sharing long-term survival under this treatment is very unlikely. Sitting there as a survivor from the #PLX4032 Phase I Braf trail of January 2010, later adding the Mek to my regiment, I was surprised. I feel there are a few of us out there whose bodies beat the odds continuing to thrive long-term years after treatment. I can’t be the only super responder.
My passion is helping patients understand options while inspiring hope. Remember no matter what stage you are fighting you are not alone! There are resources to help you navigate the process.
My journey on the Phase I trial for PLX4032 was not easy, I feel that giving back through volunteering at the Melanoma Research Foundation and working with Rose Wang and the team at 1104Health to help patients and local oncologists connect with key physician investigators to increase patient outcomes is my purpose.
1104Health is here to support patients and oncologists. Visit our website for more information https://www.1104health.com/
#Cancer
#Clinicaltrails
#PatientAdvocacy